Novo Nordisk Pharma Korea, Ltd.
Seoul, 01000, South Korea
NCT Number: NCT07673822
This study tests the prevalence and characteristics of overlapping obesity, type 2 diabetes (T2D), cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic dysfunction-associated steatotic liver disease [MASLD/Metabolic Dysfunction-Associated Steatohepatitis (MASH)], osteoarthritis, hypertension, and dyslipidemia. The purpose of the study is to measure how common cardiovascular, kidney, and metabolic diseases are in the Korean adult population and how often they occur together (overlap) over time (2013-2023). Participants will not receive any study medicine as this is an observational analysis of existing survey data. The study does not involve a new investigational drug; it analyses health and outcome data collected in routine practice and national surveys.
Interested in participating?
Request Info19 year and older
All sexes
Observational
Seoul, 01000, South Korea
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Primary Analysis:
Secondary Analysis (Subgroup Cohorts):
Exclusion criteria
Primary Analysis:
Secondary Analysis (Subgroup Cohorts)
No treatment given
Time frame: 2013-2018 (Annually)
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Measured as descriptive statistics.
Time frame: Cohort index date (2013-2018)
Measured as descriptive statistics.
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential follow up (FU))
Measured in Hazard Ratio (HR).
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential FU)
Measured as outpatient visits, hospitalizations, and emergency room visits in terms of number of participants.
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential FU)
Measured as outpatient visits, hospitalizations, and emergency room visits in terms of rates per person-year.
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential FU)
Measured as Cumulative total costs and annualized costs per person-year in terms of means with standard deviations.
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential FU)
Measured as Cumulative total costs and annualized costs per person-year in terms of medians with Interquartile Range (IQR)
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential (FU)
Measured in Hazard Ratio (HR).
Time frame: Cohort index date (2013-2018)
Measured in proportion (%) by phenotype.
Time frame: Over cohort follow-up (2013-2023)
Measured in proportion (%).
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 years potential FU) to date of Progression
Measured as median time to progression, if estimable; number and proportion with progression
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 years potential FU) to tier change
Measured as median time to tier change, if estimable; number and proportion with tier change.
Novo Nordisk A/S
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07309094
Body Weight, Chronic Disease
Valencia, Spain
View Trial DetailsNCT03179657
Atrophy, Body Weight
View Trial DetailsNCT07248891
Chronic Disease, Chronic Kidney Disease
Mexico City, Mexico
View Trial DetailsNCT05198765
Body Weight, Diabetes Mellitus
Minneapolis, Minnesota, United States
View Trial Details